Extracellular matrix and hemidesmosome-associated proteins

The extracellular matrix (ECM) and hemidesmosome-associated proteins represent a diverse group of structural and signaling molecules that facilitate the adhesion of epithelial cells to the underlying basement membrane. Hemidesmosomes are multiprotein complexes consisting of intracellular plaque proteins like plectin and dystonin (BP230), transmembrane proteins such as integrin alpha-6 beta-4 and type XVII collagen (BP180), and extracellular ligands like laminin-332 (Walko et al., 2015, J Cell Sci). These proteins are essential for maintaining the mechanical stability of tissues, particularly the skin and mucous membranes, by linking the intermediate filament cytoskeleton to the ECM (Borradori & Sonnenberg, 1999, J Invest Dermatol). Beyond structural support, these proteins regulate vital cellular processes including proliferation, differentiation, and migration through outside-in signaling pathways (Koster et al., 2003, J Cell Biol). Genetic mutations in the genes encoding these proteins lead to various forms of epidermolysis bullosa, characterized by extreme skin fragility and blistering (Fine et al., 2014, J Am Acad Dermatol). Additionally, these proteins are frequently dysregulated in squamous cell carcinomas, where they contribute to tumor invasion and survival (Stewart & O'Connor, 2015, Cell Adh Migr). Therapeutic strategies targeting this group include gene replacement therapies for inherited defects and monoclonal antibodies to manage autoimmune responses against hemidesmosomal antigens (Lamberts et al., 2018, Br J Dermatol).

Other names

ECM-hemidesmosome proteinsDermal-epidermal junction proteinsBasement membrane zone proteinsHemidesmosome-associated proteins

The mechanisms of action for drugs associated with these proteins include gene replacement therapy to restore functional protein expression in genetic disorders like dystrophic epidermolysis bullosa, and the use of monoclonal antibodies to deplete B-cells or block inflammatory cytokines (IL-4, IL-13, IgE) to reduce the production and impact of autoantibodies targeting hemidesmosomal components in autoimmune blistering diseases (Lamberts et al., 2018, Br J Dermatol; Fine et al., 2014, J Am Acad Dermatol).